CRYSTALLINE FORM OF 3-Z-[1-(4-(N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-M ETHYL-AMINO)-ANILINO)-1-PHENYL-METHYLENE]-6-METHOXYCAR BONYL-2-INDOLINONE
The present invention provides a novel free base crystalline form of 3-z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and a preparing method thereof, and further provides a pharmaceutical formulations containing the crystalline forms and their use for the treatment of diseases, in particular for the treatment of angiogenic ocular diseases. The X-ray powder diffraction pattern of the crystalline form has a characteristic diffraction peak at a position corresponding to 2[theta] value being 6.4 +/- 0.2, and has a characteristic diffraction peak at a position corresponding to at least one of 2[theta] values selected from: 16.6 +/- 0.2, 17.4 +/- 0.2, 17.8 +/- 0.2 and 19.9 +/- 0.2.本發明提供了3-Z-[1-(4-(N-((4-甲基-呱嗪-1-基)-甲羰基)-N-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的新游離鹼晶型及其製備方法,還提供了含有所述晶型的藥物製劑及其用於治療疾病特別是用於治療血管生成性眼部疾病的用途。
